The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index; none of the 31 sources its claims cite is checked for support yet.
Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer’s disease
Open accessAbstract
While neuritic plaques and neurofibrillary tangles in older adults are correlated with cognitive impairment and severity of dementia, it has long been recognized that the relationship is imperfect as some people exhibit normal cognition despite high levels of AD pathology. We compared the cellular, synaptic and biochemical composition of midfrontal cortices in female subjects from the Religious Orders Study who were stratified into three subgroups: 1) pathological AD with normal cognition (“AD-Resilient”), 2) pathological AD with AD-typical dementia (“AD-Dementia)” and 3) pathologically normal with normal cognition (“Normal Comparison”). The AD-Resilient group exhibited preserved densities of synaptophysin-labeled presynaptic terminals and synaptopodin-labeled dendritic spines compared to the AD-Dementia group, and increased densities of GFAP astrocytes compared to both the AD-Dementia and Normal Comparison group. Further, in a discovery antibody microarray protein analysis we identified a number of candidate protein abnormalities that were associated with diagnostic group. These data characterize cellular and synaptic features and identify novel biochemical targets that may be associated with resilient cognitive brain aging in the setting of pathological AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 31 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“GFAP astrocyte densities differed among groups with post-hoc tests demonstrating increased density in the AD-Resilient group compared to both the AD-Dementia and NC groups.”
- Also stated in: § Abstract · plain
“increased densities of GFAP astrocytes compared to both the AD-Dementia and Normal Comparison group.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.2 Cellular and Synaptic Features
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“negatively correlated with synaptopodin spines (ρ=−0.45, p=0.01)”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.3 Relation of Neuropathologic Indices to Cellular and Synaptic Features
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Using one-way ANOVA, we then identified 57 proteins that distinguished the groups (Table 3), and visualized the proteins in a heat map (Figure 2b).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.4 Antibody Microarray Protein Expression Profiling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In accord with their expected relationship, pre- and postsynaptic measures were highly correlated (Spearman’s r = 0.58, p = 0.0009).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.2 Cellular and Synaptic Features
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“negatively correlated with synaptopodin spines (ρ=−0.44, p=0.02)”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.3 Relation of Neuropathologic Indices to Cellular and Synaptic Features
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“With PCA we observed tight clustering of NC cases while AD-Dementia and AD-Resilient cases were more dispersed (Figure 2a).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.4 Antibody Microarray Protein Expression Profiling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The AD-Dementia group exhibited lower measures compared to both AD-Resilient and NC groups.”
- Also stated in: § Abstract · plain
“The AD-Resilient group exhibited preserved densities of synaptophysin-labeled presynaptic terminals and synaptopodin-labeled dendritic spines compared to the AD-Dementia group”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.2 Cellular and Synaptic Features
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Post-hoc comparisons identified 16 proteins that significantly differentiated AD-Resilient and AD-Dementia groups (Table 3).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.4 Antibody Microarray Protein Expression Profiling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“They negatively correlated with NeuN neurons (ρ=−0.39, p=0.03)”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.3 Relation of Neuropathologic Indices to Cellular and Synaptic Features
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“positively correlated with GFAP astrocytes (ρ=0.49, p=0.008)”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.3 Relation of Neuropathologic Indices to Cellular and Synaptic Features
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 23
- Probably not a substantial claim. 23
- The quote only partly states this claim. 2
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Both synaptopodin spines and synaptophysin immunoexpression were preserved in AD-Resilient group, with levels comparable to those in the NC group.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.2 Cellular and Synaptic Features
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whjle not statistically significant, PHFtau tangles negatively correlated with NeuN neurons (ρ=−0.31, p=0.10)”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.3 Relation of Neuropathologic Indices to Cellular and Synaptic Features
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The NC group was especially distinct from AD-Dementia and AD-Resilient groups, but we did observe some differentiation in the expression pattern between AD-Dementia and AD-Resilient groups.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.4 Antibody Microarray Protein Expression Profiling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and synaptophysin (ρ=−0.27, p=0.16).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.3 Relation of Neuropathologic Indices to Cellular and Synaptic Features
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Brain weights were less in the AD-Dementia group compared to the AD-Resilient and NC groups but differences were not statistically significant (Table 1 and Supplement Figure).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.1 Clinical and Neuropathological Features
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immunohistochemically labeled amyloid-β plaque % areas and PHFtau neurofibrillary tangle densities in midfrontal cortex were comparable in the AD-Resilient and AD-Dementia groups and both were significantly greater in these groups than the NC group.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.1 Clinical and Neuropathological Features
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As expected, significant differences were found in frequency of apolipoprotein E ε4 allele, mini-mental state examination score, and CERAD and Braak scores.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.1 Clinical and Neuropathological Features
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“NeuN neuron density was slightly lower in the NC group compared to both the AD-Resilient and AD-Dementia groups, but differences were not significant.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.2 Cellular and Synaptic Features
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“normal synaptophysin expression in midfrontal cortex in the AD-Resilient group indicates preserved connectivity while the reduced synaptophysin expression in the AD-Dementia group suggests decreased connectivity.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is noteworthy that PCA found tight clustering of component scores of the NC cases while the cases with pathological AD, both AD-Dementia and AD-Resilient, were more variable in their distributions.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“serine/threonine-protein phosphatase (“PP2A”, an important phosphatase for tau (Iqbal, et al., 2009))”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
- Rests on an assumption: The differentially expressed proteins identified by the antibody microarray are not false positives arising from multiple comparisons.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found synaptopodin-labeled spine puncta density to be reduced in AD-Dementia as well, but densities were equivalent to normal in the AD-Resilient group.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“lymphocyte-specific protein tyrosine kinase (which phosphorylates tyrosine residues in tau, has been reported to be decreased in AD and genetically associated with AD (Scales, et al., 2011))”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
- Rests on an assumption: The differentially expressed proteins identified by the antibody microarray are not false positives arising from multiple comparisons.
In the paper
“Amyloid-β plaques and hyperphosphorylated tau neurofibrillary tangles are common age-related lesions that are presumed to play primary pathophysiological roles in the dementia of Alzheimer’s disease (AD)(Jellinger, 2009).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 1. Introduction
What the sources say
- Not checked yetcites Jellinger, 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, the Nun Study has shown discordance of cognition with pathology as well as the important effects of education, diet, linguistic ability, and childhood positive emotion on cognitive function in late life (Iacono, et al., 2009,Tyas, et al., 2007).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 1. Introduction
What the sources say
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We then filtered 10 cases from each group that were most closely matched for age and postmortem interval.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.1 Case Materials
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We excluded any cases with clinical or pathological diagnoses other than normal, MCI or AD that potentially contributed to cognitive impairment (e.g., abundant Lewy body pathology, infarcts, hippocampal sclerosis, etc.).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.1 Case Materials
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Independent publications report very high validity of differential protein expression, verified with Western blotting, and our preliminary study findings were consistent with this.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.4 Antibody Microarray
What the sources say
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Neuropathologic diagnoses of AD were established by a board-certified neuropathologist blinded to age and all clinical data according to NIA-Reagan (Hyman and Trojanowski, 1997), Braak (Braak and Braak, 1995), and CERAD (Mirra, et al., 1991) classifications.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.1 Case Materials
What the sources say
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“The midfrontal gyrus cortex (corresponding predominantly to Brodmann area 46) was chosen for semi-quantitative image analyses of AD pathology, cellular and synaptic markers because of its important role in complex cognition and its common neuropathological involvement in the spectrum of AD (Arnold, et al., 1991).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.2 Immunohistochemistry of AD Lesions, Neurons, Glia, Synapses and Spines
What the sources say
- Not checked yetcites Arnold, et al., 1991 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, we inspected the selected cases for other clinical data that might skew the relationship between pathology and cognition, i.e., unusual medical or psychiatric conditions, medicines, or causes of death, and substituted alternative cases as necessary.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.1 Case Materials
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Annual evaluations included a uniform structured interview and examination consisting of medical history, neurological examination and cognitive testing by trained personnel who are blind to previous evaluations, as previously described (Bennett, et al., 2002).”
- Also stated in: § 2.1 Case Materials · plain
“Follow-up evaluations, identical in all essential details, were performed annually by examiners blinded to previously collected data.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.1 Case Materials
What the sources say
- Not checked yetcites Bennett, et al., 2002 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § 2.1 Case Materials · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All image acquisition and analyses were conducted masked to case information.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.3 Image Acquisition and Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Data was collected in single sections that were all stained in single runs with uniform development times.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.2 Immunohistochemistry of AD Lesions, Neurons, Glia, Synapses and Spines
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The hemisphere used for diagnostic and frozen blocks alternated randomly between cases.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.1 Case Materials
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The Clontech antibody array has been used in a variety of settings since 2003 (Anderson, et al., 2003,Hatjiharissi, et al., 2007).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.4 Antibody Microarray
What the sources say
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We first limited our selection to female participants in the ROS cohort, thus minimizing sex and major lifestyle differences (given relatively similar lifestyles activities, diet, habits and healthcare of Catholic female clergy).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.1 Case Materials
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Statistical analyses further showed no significant differences among groups for education, use of hormone replacement therapy (only 1 normal comparison case had ever been on this), postmortem interval, brain weight, and presence or absence of macroscopic or microscopic infarcts, which if present, were in regions other than mid-frontal cortex.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.1 Clinical and Neuropathological Features
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This suggests that the protein expression profile of healthy brain tissues is distinct from those with abundant AD pathology and that AD pathology disrupts protein expression in non-cohesive ways.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 3. Results > 3.4 Antibody Microarray Protein Expression Profiling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Preliminary experiments with the microarray were conducted to examine the inter-experiment reliability of the platform. Aliquots of pooled tissue homogenates from two groups were run in four separate experiments and coefficient of variations (CV) were calculated for each of the protein measurements on the array. Average CV was 0.14 (SD=0.27, range 0.01 to 2.0)”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 2. Methods > 2.4 Antibody Microarray
Strength:plain· not yet calibratedn = 4Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Synaptic loss is frequently cited as the best neuropathological correlate of dementia severity in AD (Terry, et al., 1991) and has been linked to the accumulation of both amyloid-β and tau pathology (Arendt, 2009).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Cortical astrocytes maintain brain health through structural and biochemical support to neurons and endothelial cells, maintain extracellular ion balance, provide nutrients to neurons, regulate cortical blood flow, transmitter uptake and release, modulate synaptic neurotransmission and provide trophic and detoxifying support in response to injury (Sofroniew and Vinters, 2010).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
What the sources say
- Not checked yetcites Sofroniew and Vinters, 2010 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data characterize cellular and synaptic features and identify novel biochemical targets that may be associated with resilient cognitive brain aging in the setting of pathological AD.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The 507 proteins measured by the Clontech antibody microarray include proteins relevant to resilient cognition in Alzheimer’s disease.
In the paper
“Supporting this notion, Price et al. reported no measureable cognitive impairment per se in such preclinical AD cases, but degraded cognitive function in the presence of plaques and tangles (Price, et al., 2009).”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
What the sources say
- Not checked yetcites Price, et al., 2009 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An antibody microarray served as an unbiased measure of the relative expression levels of over 500 proteins that span a broad range of functional groups.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, they may introduce systematic inaccuracies that might be obviated with reference volume-based stereological approaches.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“but the challenge of multiple comparisons remains, especially in relatively small sample sizes.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“while postmortem neuropathology remains the best approach to investigate the neurobiology of uniquely human brain diseases, it only allows a snapshot of the brain as it was near the time of death, it can suggest, but not establish, causal relationships between clinical and brain data, and confounds such as agonal state and postmortem changes can alter the brains’ cellular and molecular integrity.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Our use of a pooled tissue standard as a reference in all experiments, dye swapping and calculated INR attenuated many potential pitfalls”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“These minimize operator bias, lend themselves well to larger scale, high-throughput studies, and they successfully found between group differences.”
§ Cellular, synaptic and biochemical features of resilient cognition in Alzheimer’s disease > 4. Discussion
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
There has been little postmortem investigation of neurobiological factors that might confer or be associated with resilient brain aging.
“Aside from noting such discordance in clinicopathological studies, there has been little pursuant postmortem investigation of neurobiological factors that might confer or be associated with resilient brain aging.”
The paper relies on this without support.
The correlation between Alzheimer’s disease neuropathological lesions and cognition is modest and accounts for limited variance among older adults.
“However, it is also recognized that the correlation between these neuropathological lesions and cognition is modest and accounts for a limited amount of the variance of cognition among older adults.”
The paper relies on this without support.
The 507 proteins measured by the Clontech antibody microarray include proteins relevant to resilient cognition in Alzheimer’s disease.
“The Clontech. Antibody Microarray 500 (Clontech, Mountainview, CA) was used to profile relative expression levels of 507 proteins.”
The paper relies on this without support.
Composite cognition scores from the last assessment before death accurately reflect the participants’ cognitive status relevant to group classification.
“We next stratified according to composite cognition scores from the last assessment before death and global pathology (average plaque and tangle burdens in diagnostic blocks).”
The paper relies on this without support.
The observed cellular and biochemical differences between the AD-Resilient group and the other groups are not attributable to confounds such as agonal state or postmortem changes.
“confounds such as agonal state and postmortem changes can alter the brains’ cellular and molecular integrity.”
The paper relies on this without support.
The differentially expressed proteins identified by the antibody microarray are not false positives arising from multiple comparisons.
“the challenge of multiple comparisons remains, especially in relatively small sample sizes.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some studies have reported preserved neuronal numbers and synaptic densities in the hippocampus in “preclinical/resilient AD” compared with normal and clinical AD cases [62], [108], [109].”
From Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease (2014) · cites this paper as [62]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
limma: Linear Models for Microarray Data
Smyth, G. K. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0_23 · Cited by 5,796
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Bioinformatics and Computational Biology Solutions Using R and Bioconductor
Gentleman, R. C., Carey, V. J., Huber, W. K., Irizarry, R. A., & Dudoit, S. (2005) · Statistics in the health sciences · doi:10.1007/0-387-29362-0 · Cited by 3,470
Java Treeview—extensible visualization of microarray data
Saldanha, A. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth349 · Cited by 2,991
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Flagged first, then by citations
1 of the 66 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Religious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179939 · Cited by 1,260
Self-citationThe Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
TDP-43 is a key player in the clinical features associated with Alzheimer’s disease
Josephs, K. A., Whitwell, J. L., Weigand, S. D., Murray, M. E., Tosakulwong, N., Liesinger, A. M., Petrucelli, L., Senjem, M. L., Knopman, D. S., Boeve, B. F., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1269-z · Cited by 481
Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
Jack, C. R., Wiste, H. J., Weigand, S. D., Rocca, W. A., Knopman, D. S., Mielke, M. M., Lowe, V. J., Senjem, M. L., Gunter, J. L., Preboske, G. M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70194-2 · Cited by 358
Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease
Kelly, S. C., He, B., Perez, S. E., Ginsberg, S. D., Mufson, E. J., & Counts, S. E. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0411-2 · Cited by 286
de Wilde, M. C., Overk, C., Sijben, J., & Masliah, E. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.12.005 · Cited by 287
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
Pereira, J. B., Janelidze, S., Ossenkoppele, R., Kvartsberg, H., Brinkmalm, A., Mattsson, N., Stomrud, E., Smith, R. A., Zetterberg, H., Blennow, K., et al. (2020) · Brain · doi:10.1093/brain/awaa395 · Cited by 208
Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease
James, B. D., & Bennett, D. A. (2019) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040218-043758 · Cited by 213
Self-citationBamidis, P. D., Fissler, P., Papageorgiou, S. G., Zilidou, V. I., Konstantinidis, E. I., Billis, A. S., Romanopoulou, E. D., Karagianni, M. A., Beratis, I., Tsapanou, A., et al. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00152 · Cited by 196
Role of Prenatal Hypoxia in Brain Development, Cognitive Functions, and Neurodegeneration
Nalivaeva, N. N., Turner, A. J., & Zhuravin, I. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00825 · Cited by 181
Novelty Interventions to Enhance Broad Cognitive Abilities and Prevent Dementia
Fissler, P., Küster, O. C., Schlee, W., & Kolassa, I. (2013) · Progress in brain research · doi:10.1016/b978-0-444-63327-9.00017-5 · Cited by 192
Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology
Shulman, J. M., Chen, K., Keenan, B. T., Chibnik, L. B., Fleisher, A., Thiyyagura, P., Roontiva, A., Aubin, C., Patsopoulos, N. A., Corneveaux, J. J., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2815 · Cited by 162
Self-citationZeineh, M. M., Chen, Y., Kitzler, H. H., Hammond, R., Vogel, H., & Rutt, B. K. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.022 · Cited by 151
Recent update on the heterogeneity of the Alzheimer’s disease spectrum
Jellinger, K. A. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02449-2 · Cited by 155
Socio-emotional and cognitive resilience in children with reading disabilities
Haft, S. L., Myers, C. A., & Hoeft, F. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.06.005 · Cited by 159
Cognitive and social lifestyle: links with neuropathology and cognition in late life
Bennett, D. A., Arnold, S. E., Valenzuela, M., Brayne, C., & Schneider, J. A. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1226-2 · Cited by 148
Self-citationCognitive Resilience to Psychological Stress in Military Personnel
Flood, A. P., & Keegan, R. J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.809003 · Cited by 199
Molecular and cellular pathophysiology of preclinical Alzheimer’s disease
Mufson, E. J., Ikonomović, M. D., Counts, S., Perez, S. E., Malek‐Ahmadi, M. H., Scheff, S. W., & Ginsberg, S. D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.030 · Cited by 134
Alzheimer's disease: The next frontier—Special Report 2017
Karlawish, J. H., Jack, C. R., Rocca, W. A., Snyder, H. M., & Carrillo, M. C. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.006 · Cited by 124
White, C. C., Yang, H., Yu, L., Chibnik, L. B., Dawe, R. J., Yang, J., Klein, H., Felsky, D., Ramos‐Miguel, A., Arfanakis, K., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002287 · Cited by 105
Self-citationSilva, A. R. T., Santos, A. C. F., Farfel, J. M., Grinberg, L. T., Ferretti, R. E. L., Campos, A. H. J. F. M., Cunha, I. W., Begnami, M. D., Rocha, R. M., Carraro, D. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099897 · Cited by 99
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes
Gómez-Isla, T., & Frosch, M. P. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00642-9 · Cited by 96
Effects of Prenatal Hypoxia on Nervous System Development and Related Diseases
Wang, B., Zeng, H., Liu, J., & Sun, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.755554 · Cited by 93
Emerging pathways driving early synaptic pathology in Alzheimer's disease
Briggs, C. A., Chakroborty, S., & Stutzmann, G. E. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.088 · Cited by 95
Neuropathological approaches to cerebral aging and neuroplasticity
Jellinger, K. A., & Attems, J. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.1/kjellinger · Cited by 94
Sex-specific effects of microglial activation on Alzheimer’s disease proteinopathy in older adults
Casaletto, K. B., Nichols, E., Aslanyan, V., Simone, S. M., Rabin, J. S., Joie, R. L., Brickman, A. M., Dams-O’Connor, K., Palta, P., Kumar, R. G., et al. (2022) · Brain · doi:10.1093/brain/awac257 · Cited by 92
Self-citationDendritic Spines: Mediators of Cognitive Resilience in Aging and Alzheimer’s Disease
Walker, C. K., & Herskowitz, J. H. (2021) · The Neuroscientist · doi:10.1177/1073858420945964 · Cited by 86
de Vries, L. E., Huitinga, I., Kessels, H. W. H. G., Swaab, D. F., & Verhaagen, J. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00719-7 · Cited by 85
Carlyle, B. C., Kandigian, S. E., Kreuzer, J., Das, S., Trombetta, B. A., Kuo, Y., Bennett, D. A., Schneider, J. A., Petyuk, V. A., Kitchen, R. R., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.012 · Cited by 65
Self-citationSynaptophysin and Synaptojanin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease
Martin, S. B., Dowling, A. L. S., Lianekhammy, J., Lott, I. T., Doran, E., Murphy, M. P., Beckett, T. L., Schmitt, F. A., & Head, E. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140795 · Cited by 64
Complement-mediated synapse loss in Alzheimer’s disease: mechanisms and involvement of risk factors
Wen, L., Bi, D., & Shen, Y. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.11.010 · Cited by 64
Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer’s Disease
Mahady, L. J., Nadeem, M., Malek‐Ahmadi, M. H., Chen, K., Perez, S. E., & Mufson, E. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171032 · Cited by 61
Tau neurotoxicity and rescue in animal models of human Tauopathies
Krüger, L., & Mandelkow, E. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.09.004 · Cited by 63
Maggio, N., & Vlachos, A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.041 · Cited by 55
Hippocampal Transcriptomic Profiles: Subfield Vulnerability to Age and Cognitive Impairment
Ianov, L., Both, M. D. D., Chawla, M. K., Rani, A., Kennedy, A. J., Piras, I. S., Day, J. J., Siniard, A. L., Kumar, A., Sweatt, J. D., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00383 · Cited by 57
Late‐life physical activity relates to brain tissue synaptic integrity markers in older adults
Casaletto, K., Ramos‐Miguel, A., VandeBunte, A., Memel, M., Buchman, A., Bennett, D., & Honer, W. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12530 · Cited by 53
Self-citationSynaptic Compensatory Plasticity in Alzheimer’s Disease
Bhembre, N., Bonthron, C., & Opazo, P. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0379-23.2023 · Cited by 56
Geerts, H., Wikswo, J. P., van der Graaf, P. H., Bai, J. P. F., Gaiteri, C., Bennett, D. A., Swalley, S. E., Schuck, E. L., Kaddurah‐Daouk, R., Tsaioun, K., et al. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12478 · Cited by 49
Self-citationYu, Q., Du, F., Douglas, J. T., Yu, H., Yan, S. S., & Yan, S. F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170283 · Cited by 51
Correlation of Cognitive Resilience, Cognitive Flexibility and Impulsivity in Attempted Suicide
Ram, D., Chandran, S., Sadar, A., & Gowdappa, B. (2019) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_189_18 · Cited by 55
Zolochevska, O., & Taglialatela, G. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160518142110 · Cited by 49
Hampel, H. J., Lista, S., Néri, C., & Vergallo, A. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101662 · Cited by 47
Pettigrew, C. A., Soldan, A., Zhu, Y., Cai, Q., Wang, M., Moghekar, A., Miller, M. I., Singh, B., Martinez, O., Fletcher, E. M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.003 · Cited by 47
Perez, S. E., He, B., Nadeem, M., Wuu, J., Scheff, S. W., Abrahamson, E. E., Ikonomović, M. D., & Mufson, E. J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.016 · Cited by 47
Cognitive Reserve from the Perspective of Preclinical Alzheimer Disease
Soldan, A., Pettigrew, C. A., & Albert, M. (2019) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.11.006 · Cited by 46
Xue, D., Li, P. W. C., Yu, D. S. F., & Lin, R. S. Y. (2023) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2023.104592 · Cited by 48
Strehl, A., Lenz, M., Itsekson-Hayosh, Z., Becker, D., Chapman, J., Deller, T., Maggio, N., & Vlachos, A. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.033 · Cited by 39
Sekiya, M., Wang, M., Fujisaki, N., Sakakibara, Y., Quan, X., Ehrlich, M. E., De Jager, P. L., Bennett, D. A., Schadt, E. E., Gandy, S., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0530-9 · Cited by 38
Self-citationHuang, Z., Merrihew, G. E., Larson, E. B., Park, J., Plubell, D., Fox, E. J., Montine, K. S., Latimer, C. S., Dirk Keene, C., Zou, J. Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38376-x · Cited by 37
Takahashi, A., Watanabe, T., Fujita, T., Hasegawa, T., SAITO, M., & Suganuma, M. (2014) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2014.921553 · Cited by 33
Zafar, S., Shafiq, M., Younas, N., Schmitz, M., Ferrer, I., & Zerr, I. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170237 · Cited by 31
Well-Being and Cognitive Resilience to Dementia-Related Neuropathology
Willroth, E. C., James, B. D., Graham, E. K., Kapasi, A., Bennett, D. A., & Mroczek, D. K. (2022) · Psychological Science · doi:10.1177/09567976221119828 · Cited by 34
Self-citationde Vries, L. E., Jongejan, A., Fortes, J. M., Balesar, R. A., Rozemüller, A. J. M., Moerland, P. D., Huitinga, I., Swaab, D. F., & Verhaagen, J. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01760-9 · Cited by 29
Datta, A., Chai, Y. L., Tan, J. M., Lee, J. H., Francis, P. T., Chen, C., Sze, S. K., & Lai, M. K. P. (2017) · Molecular Brain · doi:10.1186/s13041-017-0316-9 · Cited by 28
Cognitive resilience in Alzheimer’s disease: Mechanism and potential clinical intervention
Jia, B., Xu, Y., & Zhu, X. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102711 · Cited by 30
The interplay between age at menopause and synaptic integrity on Alzheimer’s disease risk in women
Alexander, M. W., Honer, W. G., Saloner, R., Galea, L. A. M., Bennett, D. A., Rabin, J. S., & Casaletto, K. B. (2025) · Science Advances · doi:10.1126/sciadv.adt0757 · Cited by 32
Self-citationThe transcriptional landscape of Alzheimer’s disease and its association with Wnt signaling pathway
Martínez, M., & Inestrosa, N. C. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.029 · Cited by 26
Branch, A., Monasterio, A., Blair, G. A., Knierim, J. J., Gallagher, M., & Haberman, R. P. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.12.015 · Cited by 24
Whole genome deconvolution unveils Alzheimer’s resilient epigenetic signature
Berson, E., Sreenivas, A., Phongpreecha, T., Perna, A., Grandi, F. C., Xue, L., Ravindra, N. G., Payrovnaziri, S. N., Mataraso, S. J., Kim, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40611-4 · Cited by 25
Cerebrospinal Fluid and Brain Proteoforms of the Granin Neuropeptide Family in Alzheimer’s Disease
Quinn, J. P., Ethier, E. C., Novielli, A., Malone, A., Ramirez, C. E., Salloum, L., Trombetta, B. A., Kivisäkk, P., Bremang, M., Selzer, S., et al. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00341 · Cited by 24
Self-citationBriggs, C. A., Schneider, C., Richardson, J. C., & Stutzmann, G. E. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.013 · Cited by 26
Novel approaches to increase synaptic resilience as potential treatments for Alzheimer’s disease
Pham, A. Q., & Dore, K. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.03.032 · Cited by 21
Prescott, J. W., Doraiswamy, P. M., Gamberger, D., Benzinger, T. L. S., Petrella, J. R., & for the Dominantly Inherited Alzheimer Network (2021) · Radiology · doi:10.1148/radiol.2021210383 · Cited by 21
Koh, M. T., Branch, A., Haberman, R. P., & Gallagher, M. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.02.019 · Cited by 18
Cortical proteins may provide motor resilience in older adults
Buchman, A. S., Yu, L., Oveisgharan, S., Petyuk, V., Tasaki, S., Gaiteri, C., Wilson, R. S., Grodstein, F., Schneider, J. A., Klein, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90859-3 · Cited by 18
Self-citationMorgan, G. R., & Carlyle, B. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-57104-z · Cited by 17
Challenges in the Neuropathological Diagnosis of Dementias
Jellinger, K. A. (2012) · International Journal of Neuropathology · doi:10.7726/ijn.2013.1002 · Cited by 15
Telpoukhovskaia, M. A., Hadad, N., Gurdon, B., Dai, Y., Ouellette, A. R., Neuner, S. M., Dunn, A. R., Willcox, J. A. L., Wu, Y., Dumitrescu, L. C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.12.487877 · Cited by 13
Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins
Casaletto, K. B., Zetterberg, H., Blennow, K., Brinkmalm, A., Honer, W. G., Schneider, J. A., Bennett, D. A., Djukic, N. A., You, M. Y., Weiner‐Light, S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012145 · Cited by 14
Self-citationUnderstanding the molecular basis of resilience to Alzheimer’s disease
Montine, K. S., Berson, E., Phongpreecha, T., Huang, Z., Aghaeepour, N., Zou, J., MacCoss, M. J., & Montine, T. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1311157 · Cited by 14
Proteomic Insight Into Alzheimer's Disease Pathogenesis Pathways
Ryu, T., Kim, K., Asiimwe, N., & Na, C. H. (2025) · PROTEOMICS · doi:10.1002/pmic.202400298 · Cited by 12
Proteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression
Wisch, J. K., Butt, O. H., Gordon, B. A., Schindler, S. E., Fagan, A. M., Henson, R. L., Yang, C., Boerwinkle, A. H., Benzinger, T. L. S., Holtzman, D. M., et al. (2023) · Brain · doi:10.1093/brain/awac484 · Cited by 11
Seixas, A. A., Rajabli, F., Pericak‐Vance, M. A., Jean‐Louis, G., Harms, R., & Tarnanas, I. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.899080 · Cited by 11
Revisiting a Telencephalic Extent of the Ascending Reticular Activating System
Miyawaki, E. K., Bhattacharyya, S., & Torre, M. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01339-3 · Cited by 9
DNA methylation signature of a lifestyle-based resilience index for cognitive health
Zhang, W. Y., Lukacsovich, D., Young, J. I., Gomez, L., Schmidt, M. A., Martin, E. R., Kunkle, B. W., Chen, X. S., O’Shea, D. M., Galvin, J. E., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01733-7 · Cited by 11
Self-citationVerpoort, B., Amado, L., Vandensteen, J., Leysen, E., Dascenco, D., Vandenbempt, J., Lemmens, I. H., Wauman, J., Vennekens, K. M., Escamilla‐Ayala, A., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.04.025 · Cited by 10
Predicting brain amyloid load with digital and blood-based biomarkers
Chen, W., Liao, Y., Shi, X., Su, F., Kong, H., Fang, Y., Zheng, Y., Zhou, J., Liu, G., Zhou, X., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01801-y · Cited by 9
Molecular mechanisms of aging in the pathogenesis of Alzheimer’s disease
Kakkar, A., Singh, H., Singh, B. K., Chauhan, K., Chopra, S., Chopra, H., & Mishra, A. K. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00243-y · Cited by 9
Saloner, R., Fonseca, C. S., Paolillo, E. W., Asken, B. M., Djukic, N. A., Lee, S. Y., Nilsson, J., Brinkmalm, A., Blennow, K., Zetterberg, H., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201165 · Cited by 8
Hrynchak, M. V., Rierola, M., Golovyashkina, N., Penazzi, L., Pump, W. C., David, B., Sündermann, F., Brandt, R., & Bakota, L. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00016 · Cited by 7
Step, K., Leal, T. P., Waldo, E., Madula, L., Swart, Y., Hernández, C. F., Kim, J. J., Bandrés‐Ciga, S., (GP2), G. P. G. P., Mata, I. F., et al. (2025) · medRxiv · doi:10.1101/2025.08.01.25331910 · Cited by 6
Counts, S., Beck, J. S., Maloney, B., Malek‐Ahmadi, M. H., Ginsberg, S. D., Mufson, E. J., & Lahiri, D. K. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70019 · Cited by 6
Brichko, R., Soldan, A., Zhu, Y., Wang, M., Faria, A. V., Albert, M., & Pettigrew, C. A. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.859826 · Cited by 6
Pan, W., Teng, Y., Han, X., Liu, S., Pang, X., Wang, L., & Zhao, M. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100193 · Cited by 5
Self-citationYang, Z. X., Sheng, J., Zhang, Q., Zhao, X., Song, Y., Dong, G., Zhang, R., Zhao, H., Wang, J., Pan, R., et al. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin26584 · Cited by 7
Sokolov, P. M., Валентиновна, Е. И., Karaulov, A. V., Sukhanova, A. V., & Nabiev, I. R. (2024) · Biosensors · doi:10.3390/bios14070353 · Cited by 5
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
Bennett, D. A. (2013) · Neurology · doi:10.1212/01.wnl.0000427396.91304.3d · Cited by 5
Self-citationWell-being and Cognitive Resilience to Dementia-related NeuropathologyPreprint
Willroth, E. C., James, B. D., Graham, E. K., Kapasi, A., Bennett, D. A., & Mroczek, D. K. (2022) · doi:10.31234/osf.io/sbh85 · Cited by 5
Self-citationCarlyle, B. C., Kandigian, S. E., Kreuzer, J., Das, S., Trombetta, B. A., Kuo, Y., Bennett, D. A., Schneider, J. A., Petyuk, V., Kitchen, R. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.31.230680 · Cited by 4
Self-citationDirect evidence for dendritic spine compensation and regeneration in Alzheimer's disease models
Bhembre, N., Boskovic, Z., Willshaw, J. L., Castello-Waldow, T. P., Bonthron, C., Paolino, A., & Opazo, P. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70829 · Cited by 3
Alfateh, M., Vasconcelos, C., Choker, A. H., & Mohammadaein, H. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151774 · Cited by 3
Telpoukhovskaia, M. A., Murdy, T. J., Marola, O. J., Charland, K., MacLean, M., Luquez, T., Lish, A. M., Neuner, S. M., Dunn, A. R., Onos, K. D., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12458 · Cited by 2
Molecular Targeting and Translational Research for New Therapeutic Strategies on Alzheimer's Disease
Takata, K. (2013) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.13-00219 · Cited by 3
Cerebral lactate metabolism and memory: Implications for Alzheimer's disease
Harris, R. A. (2017) · Scholarship@Western (Western University) · Cited by 3
Abbate, C., & Gallucci, A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251374319 · Cited by 2
Development of early biomarkers of Alzheimer's disease: A precision medicine perspective
Sarkar, S., Das, N., & Sambamurti, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00006-x · Cited by 2
Xue, D., Yu, D. S. F., Yue, L., Sheng, M., & Li, P. W. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251401560 · Cited by 2
Xue, D., Hu, Y., Zhang, R., & Li, J. (2025) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2025.105757 · Cited by 1
Metadata
- Authors
- Arnold, S. E., Louneva, N., Cao, K., Wang, L.-S., Han, L.-Y., Wolk, D. A., Negash, S., Leurgans, S. E., Schneider, J. A., Buchman, A. S., Wilson, R. S., & Bennett, D. A.
- Affiliations
- University of Pennsylvania (US)
- Rush University (US)
- ORCID
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 34
- Issue
- 1
- Pages
- 157-168
- ISSN
- 0197-4580 (ISSN-L)
- PMC
- PMC3478410
- OpenAlex
- W2046582067
- Semantic Scholar
- 35b7b967d421550d0fbfcd374180037594e42757
- Cited by
- 123
- References
- 66
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 5 · 2023: 10 · 2022: 17 · 2021: 7 · 2020: 7 · 2019: 10 · 2018: 5 · 2017: 9 · 2016: 6 · 2015: 3 · 2014: 9 · 2013: 9
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG039478, R01AG15819, P30AG10161, P30AG10124)
- Marian S. Ware Alzheimer's Program/National Philanthropic Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- Alzheimer's disease, cognitive resilience, synaptophysin, synaptopodin, presynaptic terminals, dendritic spines, astrocytes, glial fibrillary acidic protein, antibody microarrays, protein biomarkers, dementia, Religious Orders Study, brain aging
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition Disorders, Female, Glial Fibrillary Acidic Protein, Humans, Male, Nerve Tissue Proteins, Neurons, Phosphopyruvate Hydratase, Synapses, tau Proteins, Protein Array Analysis, Microscopy, Electron, Transmission
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
